Mod-GRF(1-29) vs Triptorelin
A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.
Mod-GRF(1-29)
Mod-GRF(1-29) is a stabilized analog of growth hormone-releasing hormone (GHRH) that spans residues 1–29 of the native peptide. Unlike CJC-1295 (which includes a Drug Affinity Complex for multi-day half-life), Mod-GRF(1-29) has a short ~30-minute active window — mimicking the natural GHRH pulse pattern. It is the preferred GHRH component for precise, pulsatile GH protocols when combined with a GHRP.
Full profileTriptorelin
Potent synthetic GnRH agonist approximately 100× more potent than native GnRH. Used clinically for prostate cancer, endometriosis, and precocious puberty via sustained suppression. A single low dose (100mcg IM) is studied as a 'PCT restart' strategy that exploits the initial LH/FSH flare before receptor desensitization sets in.
Full profile| Mod-GRF(1-29) | Triptorelin | |
|---|---|---|
| Category | Performance & Growth Hormone | Performance & Growth Hormone |
| Also known as | Modified GRF(1-29), CJC-1295 without DAC, Tetrasubstituted GRF, Sermorelin analog | GnRH agonist, Decapeptyl, Trelstar, D-Trp6-LHRH |
| Evidence | Research-stage | Research-stage |
| Dosing range | 100mcg–200mcg mcg, 2–3x daily, co-administered with a GHRP (pre-sleep, pre-workout, and/or upon waking) | 50mcg–200mcg mcg, Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical) |
| Administration | Subcutaneous injection, Intramuscular injection | Intramuscular injection, Subcutaneous injection |
| Key side effects | Water retention (mild, dose-dependent), Tingling / numbness in extremities (carpal tunnel-like at high doses), Increased appetite (via GHRP component — less with Mod-GRF alone), Flushing or warmth at injection site | Initial testosterone surge followed by suppression (with repeated dosing), Hot flashes, Decreased libido, Bone density loss (long-term repeated dosing) |
| Cited sources | 2 references | 2 references |
Key differences
- Administration: Mod-GRF(1-29) — Subcutaneous injection, Intramuscular injection; Triptorelin — Intramuscular injection, Subcutaneous injection.
- Frequency: Mod-GRF(1-29) is typically 2–3x daily, co-administered with a GHRP (pre-sleep, pre-workout, and/or upon waking); Triptorelin is Single-dose for PCT restart; every 2–4 weeks for sustained suppression (clinical).
How each works
Mod-GRF(1-29)
Native GHRH(1-29) is rapidly cleaved by plasma dipeptidyl peptidase IV (DPP-IV) within 2–3 minutes. Mod-GRF(1-29) incorporates four amino acid substitutions (positions 2, 8, 15, 27) that resist DPP-IV degradation, extending the half-life to approximately 30 minutes while preserving GHRH receptor binding affinity. This creates a half-life window aligned with physiological GH pulsatility, making it suitable for 2–3x daily injections that mimic natural GH release patterns.
Triptorelin
Triptorelin produces a biphasic response: an initial agonist surge of LH and FSH (the 'flare effect') followed by complete pituitary desensitization with continued use. The single-dose PCT protocol leverages only the initial flare to jumpstart testosterone production. Clinical data supports LH surges of 10–20× baseline within hours of the first dose.
This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.